Ask AI
See Activity Collection
ProCE Banner Activity

Identifying Atypical EGFR Alterations and Personalizing First-line Treatment

Slideset

Review these downloadable slides on the molecular heterogeneity of atypical EGFR mutations in NSCLC and the implications for biomarker testing and personalized first-line treatment selection. Current guideline recommendations, tissue- and plasma-based molecular testing strategies, and clinical trial evidence supporting targeted therapies for uncommon EGFR mutations, including G719X, S768I, and L861Q, as well as EGFR exon 20 insertions, are highlighted. Key findings from the ACHILLES, UNICORN, CHRYSALIS-2, PAPILLON, and WU-KONG28 trials support the efficacy of afatinib, osimertinib, amivantamab plus lazertinib, amivantamab plus chemotherapy, and sunvozertinib in molecularly defined patient populations. Practical considerations for individualized treatment selection include mutation subtype, CNS involvement, treatment-related toxicity, and patient preferences.

Released: November 12, 2026

Begin Activity

Share

Faculty

Alexander Spira

Alexander Spira, MD, PhD, FACP

CEO
Next Oncology
Fairfax, Virginia

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is intended for oncologists, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals who care for patients with EGFR-mutant NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guideline recommendations and emerging clinical evidence to optimize comprehensive biomarker testing and the identification of atypical EGFR alterations in patients with NSCLC

  • Individualize treatment selection and sequencing for patients with atypical EGFR-mutant NSCLC by integrating molecular subtype, patient-specific factors, and the latest efficacy and safety data

  • Incorporate molecular reassessment and an understanding of resistance mechanisms into evidence-based treatment decisions following disease progression

  • Implement multidisciplinary strategies to proactively monitor and manage treatment-related adverse events, optimize adherence, and support patient-centered care across the treatment continuum